ROS1
11 drugsROS Proto-Oncogene 1
Predictive biomarker for patient selection in 12 indications
Understanding ROS1
What it means: ROS1 rearrangements create fusion proteins similar to ALK. Found in ~1-2% of non-small cell lung cancers.
Why it matters: ROS1+ cancers respond to crizotinib (FDA-approved) and other ALK/ROS1 inhibitors like entrectinib.
Testing: Tested via FISH (break-apart probe), IHC (screening), or NGS for fusion identification.
11
Approved Drugs
12
Indications
10
Companies
ROS1 is a precision-medicine biomarker linked to 11 FDA-approved targeted drugs from 10 companies, spanning 12 indications including Non-Small Cell Lung Cancer, Solid Tumors, Medullary Thyroid Cancer. Explore the targeted therapies, indications, testing methods, and companies developing ROS1 drugs below.
Search ROS1 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting ROS1
| Drug | Company | Therapeutic Area |
|---|---|---|
| ALUNBRIG | Takeda | Oncology |
| AUGTYRO | Bristol-Myers Squibb | Oncology |
| CABOMETYX | EXELIXIS | Oncology |
| COMETRIQ | EXELIXIS | Oncology |
| ENSACOVE | XCOVERY | Oncology |
| IBTROZI | NUVATION | Oncology |
| LORBRENA | Pfizer | Oncology |
| RESNIBEN | AZURITY | Oncology |
| ROZLYTREK | Roche | Oncology |
| XALKORI | PF PRISM CV | Oncology |
| ZYKADIA | Novartis | Oncology |
ROS1 Indications
Non-Small Cell Lung Cancer Solid Tumors Medullary Thyroid Cancer Anaplastic Large Cell Lymphoma Inflammatory Myofibroblastic Tumor ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adults NTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 month Advanced renal cell carcinoma Hepatocellular carcinoma previously treated with sorafenib Locally advanced or metastatic differentiated thyroid cancer Well-differentiated pancreatic neuroendocrine tumors Well-differentiated extra-pancreatic neuroendocrine tumors